UY39104A - Compuestos y métodos para modular la expresión de scn1a - Google Patents

Compuestos y métodos para modular la expresión de scn1a

Info

Publication number
UY39104A
UY39104A UY0001039104A UY39104A UY39104A UY 39104 A UY39104 A UY 39104A UY 0001039104 A UY0001039104 A UY 0001039104A UY 39104 A UY39104 A UY 39104A UY 39104 A UY39104 A UY 39104A
Authority
UY
Uruguay
Prior art keywords
dysfunctions
compounds
methods
pharmaceutical compositions
modulate
Prior art date
Application number
UY0001039104A
Other languages
English (en)
Spanish (es)
Inventor
M Freier Susan
Jafar-nejad Paymaan
Frank Rigo
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of UY39104A publication Critical patent/UY39104A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7115Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/334Modified C
    • C12N2310/33415-Methylcytosine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/352Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527Other alkyl chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
UY0001039104A 2020-02-28 2021-03-01 Compuestos y métodos para modular la expresión de scn1a UY39104A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062983555P 2020-02-28 2020-02-28
US202063085111P 2020-09-29 2020-09-29

Publications (1)

Publication Number Publication Date
UY39104A true UY39104A (es) 2021-08-31

Family

ID=77491960

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039104A UY39104A (es) 2020-02-28 2021-03-01 Compuestos y métodos para modular la expresión de scn1a

Country Status (6)

Country Link
US (1) US20230043648A1 (https=)
EP (1) EP4110919A4 (https=)
JP (1) JP2023515974A (https=)
TW (1) TW202140788A (https=)
UY (1) UY39104A (https=)
WO (1) WO2021174036A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7507093B2 (ja) * 2018-03-21 2024-06-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 17β-水酸化ステロイド脱水素酵素13型(HSD17B13)iRNA組成物およびその使用方法
EP4392562A4 (en) * 2021-08-27 2025-09-24 Ionis Pharmaceuticals Inc COMPOUNDS AND METHODS FOR MODULATING SCN1A EXPRESSION

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6453212B2 (ja) * 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. キラル制御
ES2935658T3 (es) * 2016-07-15 2023-03-09 Ionis Pharmaceuticals Inc Compuestos y métodos para la modulación de SMN2
SG11202001590RA (en) * 2017-08-25 2020-03-30 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
US10758629B2 (en) * 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
BR112021003224A2 (pt) * 2018-08-20 2021-07-20 Rogcon, Inc. oligonucleotídeos antissentido direcionados a scn2a para o tratamento de encefalopatias por scn1a
BR112022010882A2 (pt) * 2019-12-06 2022-10-04 Stoke Therapeutics Inc Oligômeros antissenso para tratamento de condições e doenças

Also Published As

Publication number Publication date
WO2021174036A1 (en) 2021-09-02
TW202140788A (zh) 2021-11-01
EP4110919A1 (en) 2023-01-04
JP2023515974A (ja) 2023-04-17
US20230043648A1 (en) 2023-02-09
EP4110919A4 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
MX2024002553A (es) Compuestos y metodos para modular la expresion de scn1a.
UY39104A (es) Compuestos y métodos para modular la expresión de scn1a
CL2023000393A1 (es) Compuestos y métodos para modular el scn2a
Bucher et al. Beyond faithful conduction: short-term dynamics, neuromodulation, and long-term regulation of spike propagation in the axon
BR112022020495A2 (pt) Composições compreendendo algas e métodos de uso das mesmas para aumentar a produção de produto animal
CR8992A (es) Analogos de biaril piperazinilpiridina sustituida
MX2017004523A (es) Composición de activo suavizante de tela.
AR077448A1 (es) Uno o una combinacion de fito-canabinoides en el tratamiento de epilepsia
NO20080282L (no) Fremgangsmate for fremstilling av hydrokarboner innen dieselomrade
NZ708823A (en) Pesticidal compositions and processes related thereto
CU20130082A7 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
MX2022004257A (es) Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales.
GT201200099A (es) Derivados que contienen antraquinona como productos agricolas bioquimicos
MX2012002996A (es) Composiciones y metodos para mejorar las funciones cognitivas y relacionadas en animales.
MX2023006744A (es) Compuestos antihelminticos que comprenden una estructura de tienopiridina.
CO2021012796A2 (es) Compuestos y métodos para modular ube3a-ats
RU2011124942A (ru) Применение кантаксантина и/или 25-он-d3 для улучшения выводимости домашней птицы
CL2011002160A1 (es) Compuestos derivados de 3-amino-2-mercaptoquinolinas sustituidas; composicion farmaceutica que contiene dichos compuestos; y su uso para tratar dolor, epilepsis, incontinencia urinaria, manias, migraña, trastornos bipolares, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.
PE20141068A1 (es) Formulaciones topicas de tipo suspension que comprenden depsipeptido ciclico
Gigova et al. Significance of microalgae-grounds and areas
AR080348A1 (es) Mezclas de compuestos plaguicidas
MX2022009505A (es) Composiciones estables de 1-metilciclopropeno y uso de las mismas.
GB2499136A (en) Fuel and base oil blendstocks from a single feedstock
UY30921A1 (es) Tetrahidro-pirazolo-piridinas ligados a carbono como moduladores de catepsina s
MX2009012330A (es) Plantas de brocoli tolerantes al trastorno del tallo hueco/quebrado.